- Home
- CELC vs TKNO Comparison
CELC vs TKNO Comparison
Compare CELC & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- TKNO
- Stock Information
- Founded
- CELC 2011
- TKNO 1996
- Country
- CELC United States
- TKNO United States
- Employees
- CELC N/A
- TKNO N/A
- Industry
- CELC Medical Specialities
- TKNO Medicinal Chemicals and Botanical Products
- Sector
- CELC Health Care
- TKNO Health Care
- Exchange
- CELC Nasdaq
- TKNO Nasdaq
- Market Cap
- CELC 440.0M
- TKNO 356.4M
- IPO Year
- CELC 2017
- TKNO 2021
- Fundamental
- Price
- CELC $51.79
- TKNO $4.69
- Analyst Decision
- CELC Strong Buy
- TKNO
- Analyst Count
- CELC 6
- TKNO 0
- Target Price
- CELC $46.50
- TKNO N/A
- AVG Volume (30 Days)
- CELC 2.9M
- TKNO 323.1K
- Earning Date
- CELC 08-14-2025
- TKNO 08-07-2025
- Dividend Yield
- CELC N/A
- TKNO N/A
- EPS Growth
- CELC N/A
- TKNO N/A
- EPS
- CELC N/A
- TKNO N/A
- Revenue
- CELC N/A
- TKNO $38,923,000.00
- Revenue This Year
- CELC N/A
- TKNO $8.73
- Revenue Next Year
- CELC N/A
- TKNO $16.53
- P/E Ratio
- CELC N/A
- TKNO N/A
- Revenue Growth
- CELC N/A
- TKNO 11.40
- 52 Week Low
- CELC $7.58
- TKNO $3.75
- 52 Week High
- CELC $53.70
- TKNO $10.37
- Technical
- Relative Strength Index (RSI)
- CELC 92.18
- TKNO 49.37
- Support Level
- CELC $38.00
- TKNO $4.39
- Resistance Level
- CELC $53.40
- TKNO $4.97
- Average True Range (ATR)
- CELC 3.33
- TKNO 0.42
- MACD
- CELC 0.92
- TKNO 0.06
- Stochastic Oscillator
- CELC 89.44
- TKNO 45.52
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.